Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients

Recruiting now · Phase 3

Conditions studied: Exocrine Pancreatic Insufficiency (EPI), Pancreatitis

In brief

This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzyme replacement therapy (PERT) is commonly used to manage EPI symptoms, it can be challenging for people who rely on feeding tubes. RELiZORB, could help these patients by simplifying the delivery of the enzymes they need. However, RELiZORB has only been studied in people with EPI caused by cystic fibrosis, so its effectiveness in pancreatitis patients remains unknown. This study aims to determine whether RELiZORB is effective for individuals requiring feeding tube support after pancreatitis.

Key facts

Study ID

NCT06691893

Run by

Massachusetts General Hospital

People needed

60

Starts

2025-03-28

Expected to finish

2027-07-15

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient diagnosed with moderate or severe exocrine pancreatic insufficiency (EPI), as defined using the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) symptom score of 1.4 or greater.
• Patient diagnosed with acute, recurrent acute pancreatitis or subacute pancreatitis. Subacute pancreatitis is defined as recent diagnosis of acute pancreatitis with sequelae of the acute episode including infection, pseudocyst, walled-off pancreatic necrosis.
• Patient is currently admitted to the hospital at the time of study enrollment.
• Patient requiring at least 50% of daily caloric and fluid intake through enteral tube feeds.
• Patient is able and willing to provide informed consent.

You may not qualify if…

• Patient with chronic pancreatitis
• Patient is currently intubated and unable to provide consent
• Patient with active gastrointestinal tract cancer
• Patient requiring less than 50% of nutritional support at time of enrollment
• Patient is unable to tolerate any form of enteral nutrition

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.